Related Experiment Video

Updated: Mar 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Rivaroxaban as an Antithrombotic Agent in a Patient With ST-Segment Elevation Myocardial Infarction and Left

Rajeev Seecheran1, Valmiki Seecheran2, Sangeeta Persad3

  • 1The University of the West Indies, St Augustine, Trinidad and Tobago.

Journal of Investigative Medicine High Impact Case Reports
|May 26, 2017
PubMed

Insights

A patient with ST-segment elevation acute coronary syndrome (STE-ACS) and left ventricular thrombus experienced complete clot dissolution. This was achieved using rivaroxaban, a direct oral factor Xa inhibitor, alongside dual antiplatelet therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Left ventricular (LV) thrombi formation after anterior myocardial infarction (MI) has decreased with modern treatments.
  • Standard anticoagulation with warfarin carries a risk of major bleeding complications.
  • Novel anticoagulants may offer a safer alternative for managing LV thrombi.

Purpose of the Study:

  • To present a case of successful LV thrombus dissolution.
  • To evaluate the safety and efficacy of rivaroxaban in managing LV thrombi in a patient with STE-ACS.

Main Methods:

  • A patient with STE-ACS and LV thrombus was treated with aspirin and ticagrelor.
  • The patient received a 3-month course of rivaroxaban in addition to dual antiplatelet therapy.
  • Echocardiography was used to monitor LV thrombus resolution.

Main Results:

  • Complete dissolution of the left ventricular thrombus was achieved after 3 months of rivaroxaban treatment.
  • The patient tolerated the rivaroxaban regimen without major bleeding complications.
  • This case demonstrates the potential of rivaroxaban in managing LV thrombi post-MI.

Conclusions:

  • Rivaroxaban, a direct oral factor Xa inhibitor, can be effective in achieving LV thrombus resolution.
  • Combining rivaroxaban with dual antiplatelet therapy may be a viable strategy for patients with STE-ACS and LV thrombi.
  • Further research is warranted to confirm the safety and efficacy of rivaroxaban in this patient population.

Keywords:
STE-ACSleft ventricular thrombusrivaroxabanticagrelor

More Related Videos

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

3.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
425
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
345
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
565
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.0K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K